Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 7/20 | 0.58 |
| ▸ | SRC | P12931 | 3/20 | 0.58 |
| ▸ | GSK3B | P49841 | 2/20 | 0.58 |
| ▸ | IGF1R | P08069 | 3/20 | 0.47 |
| ▸ | AURKA | O14965 | 7/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.42 |
| ▸ | CDK2 | P24941 | 8/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.42 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5068333 | 0.84 | AURKB (0.64) | AURKBSRCGSK3BIGF1RAURKA | |
| SCHEMBL12431001 | 0.82 | AURKB (0.64) | AURKBSRCGSK3BIGF1RAURKA | |
| SCHEMBL12430989 | 0.78 | SRC (0.74) | AURKBSRCGSK3BIGF1RAURKA | |
| SCHEMBL10294768 | 0.76 | AURKB (0.67) | AURKBSRCGSK3BIGF1RAURKA | |
| SCHEMBL10295014 | 0.74 | AURKB (0.64) | AURKBSRCGSK3BIGF1RAURKA | |
| SCHEMBL13221256 | 0.74 | AURKB (0.53) | AURKBSRCGSK3BIGF1RAURKA | |
| SCHEMBL12430554 | 0.73 | GSK3B (1.00) | AURKBSRCGSK3BAURKAAURKC | |
| SCHEMBL13221255 | 0.73 | AURKB (0.52) | AURKBSRCGSK3BIGF1RAURKA | |
| SCHEMBL3037063 | 0.73 | AURKB (0.51) | AURKBSRCGSK3BIGF1RAURKA | |
| SCHEMBL4827752 | 0.73 | AURKB (0.51) | AURKBSRCGSK3BIGF1RAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304414-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-06 | — | — | US | claimed |
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-20 | — | — | US | claimed |
| EP-1345929-B1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2006-05-17 | — | — | EP | claimed |
| US-20040157893-A1 | Pyrazole compounds useful as protein kinase inhibitors | BEBBINGTON DAVID (GB) | 2004-08-12 | — | — | US | claimed |
| US-20030004164-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-01-02 | — | — | US | claimed |
| US-8304414-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-06 | — | — | US | disclosed |
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-20 | — | — | US | disclosed |
| US-7427681-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004164-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | AURKB 7/4885SRC 458/4885GSK3B 3/4885 |
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | AURKC, AURKA, CDK3 | AURKB 5/4885SRC 429/4885GSK3B 4/4885 |
| US-20040157893-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | AURKB 5/4885SRC 450/4885GSK3B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.